MYC and breast carcinoma: demonstrated that miR-155 increased the glucose metabolism rate and mediated breast cancer cell expansion by targeting FOXO3a to regulate the cMYC oncogene in vivo and in deletion mouse models of breast cancer; similar results have been obtained with human triple-negative breast tumour cells (19).